# Refractory Crohn’s Disease Responsive to Dietary Therapy: A Case Report

## TL;DR

A patient with Crohn's disease unresponsive to medications found symptom relief through an anti-inflammatory diet, suggesting dietary therapy as a potential alternative.

## Contribution

This case report highlights the effectiveness of anti-inflammatory diets in treating refractory Crohn’s disease when pharmaceuticals fail.

## Key findings

- The patient experienced temporary relief from various medications but eventually failed to respond to all.
- Adopting an anti-inflammatory diet led to a reduction in disease symptoms and progression.
- Dietary therapy may be a viable option for patients who develop antibodies to medications.

## Abstract

Crohn’s disease is a type of inflammatory bowel disease (IBD) that typically presents in the second or third decade of life. There are various pharmaceutical therapies that have been developed to treat the disease's symptoms. However, some patients still do not find relief with these medications and turn to other therapies such as diet modification. The underlying cause of Crohn’s disease involves multiple factors such as uncontrolled inflammation and several genetic variants. While most current medication therapies control the symptoms that occur due to this uncontrolled level of inflammation, an anti-inflammatory diet (AID) may actually lower the level of inflammation in the gut and therefore reduce the amount of disease symptoms in Crohn’s disease. Some such diets include the IBD-AID, Crohn’s disease exclusion diet, and the Groningen AID (GrAID). This report describes a case of treatment-resistant Crohn’s disease in a patient who was given all categories of pharmaceutical therapies including prednisone, budesonide, sulfasalazine, olsalazine, 6-mercaptopurine, methotrexate, mesalamine, and adalimumab. These only gave temporary relief of symptoms and eventually failed for various reasons including allergic reaction, insufficient symptom control, and antibody formation against the medication. This prompted the patient to independently research AIDs instead. In conclusion, for patients whose disease is refractory to different treatments, or who develop antibodies to the medication, AIDs may offer a solution to reduce disease symptoms and progression. Education of healthcare professionals and patients alike is vital in order for Crohn's patients to gain the benefits from dietary therapy.